No connection

Search Results

SOPH

BEARISH
$5.28 Live
SOPHiA GENETICS SA · NASDAQ
Target $8.0 (+51.5%)
$2.58 52W Range $5.7
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026
Market cap
$378.41M
P/E
N/A
ROE
-110.0%
Profit margin
-102.2%
Debt/Equity
1.34
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
SOPH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a profit margin of -102.24%. While the company maintains a strong gross margin (67.39%) and healthy revenue growth (22.40%), these are overshadowed by massive operational losses and a bearish insider sentiment. The disconnect between the 'Strong Buy' analyst consensus and the deteriorating fundamental health suggests a highly speculative valuation. Overall, the company is burning capital rapidly with no clear path to profitability in the immediate term.

Key Strengths

Strong Gross Margin of 67.39% indicating product viability
Consistent Revenue Growth (22.40% YoY)
Healthy short-term liquidity with a Current Ratio of 1.96
Strong 1-year price recovery (+86.6%)
Positive analyst sentiment with a target price of $8.00

Key Risks

Extreme lack of profitability (Profit Margin -102.24%)
Critical financial health score (Piotroski 1/9)
Heavy insider selling by CEO and President
Negative ROE of -110% indicating value destruction
High Price-to-Book ratio (7.67) for a loss-making entity

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
22
Weak
Value
20
Future
50
Past
30
Health
10
Dividend
0
AI Verdict
High-Risk Speculative
Key drivers: Severe operational losses, Critical Piotroski score, Insider divestment, Revenue growth momentum
Confidence
90%
Value
20/100

Trades at a significant premium to book value despite negative earnings.

Positives
  • P/S ratio is moderate for the sector
Watchpoints
  • P/B of 7.67 is excessive given the losses
  • No Graham Number due to negative earnings
Future
50/100

Growth is present in top-line revenue but not translating to the bottom line.

Positives
  • 22.4% YoY revenue growth
  • Strong analyst target price ($8.00)
Watchpoints
  • Year-over-Year EPS growth is -41.7%
  • High cash burn rate
Past
30/100

Long-term trend is sharply negative despite a recent short-term bounce.

Positives
  • Recent 1-year price momentum
Watchpoints
  • 5-year return of -68.5%
  • Consistent history of earnings misses
Health
10/100

Deterministic health scores indicate a company in a very weak financial position.

Positives
  • Current Ratio > 1.5
Watchpoints
  • Piotroski F-Score of 1/9
  • Negative ROA and ROE
Dividend
0/100

Non-dividend paying growth/distress stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$5.28
Analyst Target
$8.0
Upside/Downside
+51.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SOPH and closest competitors.

Updated 2026-04-17
SOP
SOPHiA GENETICS SA
Primary
5Y
-68.5%
3Y
+3.5%
1Y
+86.6%
6M
+22.5%
1M
+7.5%
1W
+12.3%
BNR
Burning Rock Biotech Limited
Peer
5Y
-89.9%
3Y
+6.9%
1Y
+414.2%
6M
+415.7%
1M
+65.3%
1W
+9.6%
NAG
Niagen Bioscience, Inc.
Peer
5Y
-45.0%
3Y
+228.0%
1Y
-23.6%
6M
-37.2%
1M
-2.3%
1W
+4.9%
IRD
Opus Genetics, Inc.
Peer
5Y
+2.3%
3Y
-0.9%
1Y
+654.9%
6M
+173.5%
1M
+7.0%
1W
+17.8%
SRZ
Surrozen, Inc.
Peer
5Y
-78.7%
3Y
+192.2%
1Y
+223.8%
6M
+132.4%
1M
+22.9%
1W
+11.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-9.43
PEG Ratio
N/A
P/B Ratio
7.67
P/S Ratio
4.9
EV/Revenue
4.8
EV/EBITDA
-5.37
Market Cap
$378.41M

Profitability

Profit margins and return metrics

Profit Margin -102.24%
Operating Margin -85.43%
Gross Margin 67.4%
ROE -110.0%
ROA -27.85%

Growth

Revenue and earnings growth rates

Revenue Growth +22.4%
Earnings Growth N/A
Q/Q Revenue Growth +22.41%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
1.34
Moderate
Current Ratio
1.96
Good
Quick Ratio
1.72
Excellent
Cash/Share
$0.98

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
67.7%
Op. Margin
-85.3%
Net Margin
-88.4%
Total Assets
$0.2B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
2.46x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
130%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-03-03
$-0.17
+14.6% surprise
2025-11-04
$-0.2
+1.6% surprise
2025-08-05
$-0.25
-44.5% surprise

Healthcare Sector Comparison

Comparing SOPH against 470 companies in the Healthcare sector (26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-110.0%
This Stock
vs
-97.91%
Sector Avg
+12.3% (Excellent)
Profit Margin
-102.24%
This Stock
vs
-16.16%
Sector Avg
+532.6% (Superior)
Debt to Equity
1.34
This Stock
vs
3.0
Sector Avg
-55.4% (Less Debt)
Revenue Growth
22.4%
This Stock
vs
142.9%
Sector Avg
-84.3% (Slower)
Current Ratio
1.96
This Stock
vs
4.65
Sector Avg
-57.8% (Weaker)

Similar Companies

Peer comparison within the same industry

SOPH SOPHiA GENETICS SA
BEARISH
Mkt Cap
$378M
P/E
-
ROE
-110.0%
Price
$5.28
BNR Burning Rock...
BEARISH
Mkt Cap
$378M
P/E
-
ROE
-20.2%
Price
$35.07
 Compare with SOPH
NAGE Niagen Bioscience, Inc.
NEUTRAL
Mkt Cap
$376M
P/E
23.4
ROE
28.3%
Price
$4.69
 Compare with SOPH
IRD Opus Genetics, Inc.
BEARISH
Mkt Cap
$381M
P/E
-
ROE
-242.4%
Price
$5.36
 Compare with SOPH
SRZN Surrozen, Inc.
BEARISH
Mkt Cap
$371M
P/E
-
ROE
-%
Price
$31.56
 Compare with SOPH

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

XU ZHENYU
Officer
Sell
2026-04-14
600 shares · $2,980
MENU PHILIPPE
Officer
Sell
2026-04-14
1,600 shares · $7,933
MUKEN ROSS J
President
Sell
2026-04-14
2,800 shares · $13,887
XU ZHENYU
Officer
Sell
2026-04-13
8,120 shares · $38,374
CAMBLONG JURGI
Chief Executive Officer
Sell
2026-04-13
16,631 shares · $78,668
MENU PHILIPPE
Officer
Sell
2026-04-13
8,125 shares · $38,404
MUKEN ROSS J
President
Sell
2026-04-13
8,129 shares · $38,445
VAN WELL DAAN GUIDO MARIA
Officer
Sell
2026-04-10
2,400 shares · $11,201
XU ZHENYU
Officer
Sell
2026-04-09
4,736 shares · $22,726
CAMBLONG JURGI
Chief Executive Officer
Sell
2026-04-09
4,750 shares · $22,797
VAN WELL DAAN GUIDO MARIA
Officer
Sell
2026-04-09
4,849 shares · $23,286
MENU PHILIPPE
Officer
Sell
2026-04-09
4,731 shares · $22,695
MUKEN ROSS J
President
Sell
2026-04-09
4,736 shares · $22,727
CARDOZA GEORGE A.
Chief Financial Officer
Sell
2026-04-08
1,403 shares · $6,801
VALENTE MANUELA
Officer
Sell
2026-04-08
3,824 shares · $18,543
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F
20-F
2026-03-03

SOPH filed its annual 20-F report on March 3, 2026. Due to the absence of provided excerpts, specific financial highlights and risk factors are unavailable for summary.

20-F
20-F
2025-03-04

SOPH filed its 20-F annual report on March 4, 2025. Specific financial highlights and risk factors were not provided in the available filing metadata.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
3 analysts
BTIG
2026-04-15
Maintains
Buy Buy
Guggenheim
2026-01-26
Maintains
Buy Buy
BTIG
2025-11-10
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning SOPH from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile